Prior exposure to phencyclidine decreases voluntary sucrose consumption and operant performance for food reward

Pharmacology Biochemistry and Behavior

Volumn 76, Issue 3-4, 2003, Pages 393-400

  Turgeon, Sarah M ^a   Hoge, Stephen G ^a  

^a AMHERST COLLEGE   (United States)

Author keywords

Anhedonia; Apomorphine; Latent inhibition; Phencyclidine; Reward; Schizophrenia

Indexed keywords

APOMORPHINE; LITHIUM CHLORIDE; PHENCYCLIDINE; SODIUM CHLORIDE; SUCROSE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; APPETITE; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; EXPERIMENT; FOOD DEPRIVATION; FUNCTIONAL ASSESSMENT; GLUCOSE INTAKE; MALE; MEASUREMENT; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL; RAT; REWARD; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TASK PERFORMANCE; TASTE AVERSION;

ANIMALIA;

EID: 0344413544     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2003.08.019     Document Type: Article

References (36)

1. Allen R.M., Young S.J. Phencyclidine-induced psychosis. Am. J. Psychiatry. 135:1978;1081-1084.
2. Anis N.A., Berry S.C., Burton N.R., Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br. J. Pharmacol. 79:1983;565-575.
3. Bakker C.B., Amini F.B. Observations on the psychotomimetic effects of sernyl. Compr. Psychiatry. 2:1961;269-280.
4. Baruch I., Hemsley D.R., Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J. Nerv. Ment. Dis. 176:1998;598-606.
5. Beardsley P.M., Balster R.L. Behavioral dependence upon phencyclidine and ketamine in the rat. J. Pharmacol. Exp. Ther. 242:1987;203-211.
6. Carlezon W., Wise R. Phencyclidine-induced potentiation of brain stimulation reward: acute effects are not altered by repeated administration. Psychophamacology. 111:1993;208-402.
7. Carlezon W., Wise R. Microinjections of phencyclidine (PCP) and related drugs into nucleus accumbens shell potentiate medial forebrain bundle brain stimulation reward. Psychopharmacology. 128:1996;413-420.
8. Carlezon W., Wise R. Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J. Neurosci. 16:1996;3112-3122.
9. Carnoy P., Soubrie P., Puech A.J., Simon P. Performance deficit induced by low doses of dopamine agonists in rats: toward a model for approaching the neurobiology of negative schizophrenic symptomatology? Biol. Psychiatry. 21:1986;11-22.
10. Carnoy P., Ravard S., Wemerman B., Soubrie P., Simon P. Behavioral deficits induced by low doses of apomorphine in rats: evidence for a motivational and cognitive dysfunction which discriminates among neuroleptic drugs. Pharmacol. Biochem. Behav. 25:1986;503-509.
11. Ellenbroek B., Cools A. Animal models for the negative symptoms of schizophrenia. Behav. Pharmacol. 11:2000;223-233.
12. Fotlin R.W. Effects of anorectic drugs on the topography of feeding behavior in baboons. J. Pharmacol. Exp. Ther. 249:1989;101-109.
13. Gray N.S., Hemsley D.R., Gray J.A. Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol. Psychiatry Brain Res. 1:1992;83-89.
14. Haggerty G.C., Forney R.B., Johnson J.M. The effect of a single administration of phencyclidine on behavior in the rat over a 21-day period. Toxicol. Appl. Pharmacol. 75:1984;444-453.
15. Handelmann G.E., Contreras P.C., O'Donohue T.L. Selective memory impairment by phencyclidine in rats. Eur. J. Pharmacol. 140:1987;69-73.
16. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
17. Jentsch J.D., Roth R. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225.
18. Markou A., Kenny J.P. Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories. Neurotoxicity Res. 4:2002;297-313.
19. Okuyama S., Ogawa S., Nakazato A., Tomizawa K. Effect if NE-100, a novel sigma receptor ligand, on phencyclidine-induced delayed cognitive dysfunction in rats. Neurosci. Lett. 189:1995;60-62.
20. Papp M., Moryl E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. J. Phamacol. 263:1994;1-7.
21. Papp M., Willner P., Muscat R. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology. 104:1991;255-259.
22. Parker L.A. Rewarding drugs produce taste avoidance but not taste aversion. Neurosci. Biobehav. Rev. 19:1995;143-151.
23. Przegalinski E., Moryl E., Papp M. The effect of 5HT1A receptor ligands in a chronic mild stress model of depression. Neuropharmacology. 10:1995;1305-1310.
24. Roop R., Hollander J., Carelli R. Accumbens activity during a multiple schedule for water and sucrose reinforcement in rats. Synapse. 43:2002;223-226.
25. Sammut S., Goodall G., Muscat R. Acute interferon-α administration modulates sucrose consumption in the rat. Psychoneuroendocrinology. 26:2001;261-272.
26. Slifer B.L., Balster R.L., Woolverton W.L. Behavioral dependence produced by continuous phencyclidine infusion in rhesus monkeys. J. Pharmacol. Exp. Ther. 230:1984;399-406.
27. Sonders M.S., Keana J.F.W., Weber E. Phencyclidine and psychotomimetic sigma opiates: recent insights into their biochemical and physiological sites of action. Trends Neurosci. 11:1988;37-40.
28. Spielewoy C., Markou A. Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology. 28:2003;1106-1116.
29. Swerdlow N.R., Braff D.L., Hartston H., Perry W., Geyer M.A. Latent inhibition in schizophrenia. Schizophr. Res. 20:1996;91-103.
30. Turgeon S.M., Auerbach A.E., Heller M.A. The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm. Pharmacol. Biochem. Behav. 60:1998;553-558.
31. Weiner I. Neural substrates of latent inhibition: the switching model. Psychol. Bull. 108:1990;442-461.
32. Wessinger W.D., Owens S.M. Phencyclidine dependence: the relationship of dose and serum concentration to operant behavioral effects. J. Pharmacol. Exp. Ther. 258:1991;207-215.
33. Willner P., Lappas S., Cheeta S., Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology. 115:1994;454-462.
34. Zurita A., Molina V. Prior morphine facilitates the occurrence of immobility and anhedonia following stress. Physiol. Behav. 65:1999;833-837.
35. Zurita A., Murua S., Molina V. An endogenous opiate mechanism seems to be involved in stress-induced anhedonia. Eur. J. Pharmacol. 299:1996;1-7.
36. Zurita A., Martijena I., Cuadra G., Brandao M., Molina V. Early exposure to chronic variable stress facilitates the occurrence of anhedonia and enhanced emotional reactions to novel stressors: reversal by naltrexone pretreatment. Behav. Brain Res. 117:2000;163-171.